Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.58 |
| ▸ | ACACB | O00763 | 4/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15641638 | 0.82 | MTNR1A (0.59) | MTNR1AMTNR1BACACBACACAPTGS1 | |
| SCHEMBL18261069 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACAMAOA | |
| SCHEMBL21749917 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9114739 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACAMAOA | |
| SCHEMBL21749916 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9111530 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACAMAOA | |
| SCHEMBL9112634 | 0.79 | MTNR1A (0.56) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9109525 | 0.78 | MTNR1A (0.55) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL2554171 | 0.78 | MTNR1A (0.55) | MTNR1AMTNR1BACACBACACAMAOA | |
| SCHEMBL9111189 | 0.76 | ACACB (0.49) | MTNR1AMTNR1BACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563765-B1 | BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-8703758-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | MTNR1A 3124/4885MTNR1B 3503/4885ACACB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.